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Historically, the surgical management of femoral artery
complications after arteriotomy and compression has been
straightforward. Primary repair of arterial lacerations, evac-
uation of pseudoaneurysms and hematomas, and occasion-
ally, patch angioplasty are the mainstays of surgical
intervention.3-5 Infection is uncommon, and rarely is an in
situ or extra-anatomic bypass graft needed.2 However,
arterial injuries associated with the use of PSMC devices
may be more extensive and lead to unique complications
that were rarely seen before their introduction.10,11 The
purpose of our report is to identify these complications. We
describe our surgical management of these complications
and compare them with postcatheterization femoral artery
complications not associated with PSMC devices. 
PATIENTS AND METHODS
This is a retrospective review of all patients admitted to
the vascular surgery service at the Chattanooga Unit of the
University of Tennessee Department of Surgery with
femoral artery complications related to PSMC devices
between July 1, 1998, through December 1, 1999 (group
I). In all patients, the PSMC device used was the Perclose
Techstar or Prostar (Perclose, Inc, Redwood City, Calif). A
second group of patients (group II) consisted of all patients
who were admitted during the same time period with a
Peripheral vascular complications associated with per-
cutaneous interventional procedures have been well
described. Complications of femoral artery access include
pseudoaneurysm, arteriovenous fistula, arterial dissection,
laceration, infection, thrombosis, and hemorrhage.1-3 The
overall risk of complications is between 1.0% to 16%.4-6 In
an attempt to minimize these complications, percutaneous
suture–mediated closure (PSMC) devices have been devel-
oped. These devices allow for immediate closure of the
arteriotomy, leading to less patient discomfort and earlier
ambulation after a procedure. Initial studies with PSMC
devices report greater patient satisfaction and decreased
complication rates when compared with manual and
mechanical compression or plug techniques.7-9
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The management of peripheral vascular
complications associated with the use of
percutaneous suture–mediated closure devices
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Chattanooga, Tenn
Purpose: The purpose of this study is to identify the peripheral vascular complications associated with the use of per-
cutaneous suture–mediated closure (PSMC) devices and compare them with postcatheterization femoral artery com-
plications not associated with PSMC devices. 
Methods: This is a retrospective review of all patients admitted to the vascular surgery service at the Chattanooga Unit
of the University of Tennessee Department of Surgery with a peripheral vascular complication after percutaneous
femoral arteriotomy between July 1, 1998, and December 1, 1999. The complications followed the use of PSMC
devices (group I, n = 11) and traditional compression therapy (group II, n = 14) to achieve arterial hemostasis. Group
II was subdivided into patients who required operative intervention (group IIA, n = 8), and those who were treated
without operation (group IIB, n = 6).
Results: No significant difference was found between groups I and II with regard to age (P = .227), time to vascular
surgery consultation (P = .987), or diagnostic versus therapeutic catheterization (P = .897). A significant difference
was found with regard to mean pseudoaneurysm size (group I = 5.9 cm, group II 2.9 cm; P = .003). Ultrasound com-
pression was successfully performed in 66.6% of group II patients, but no (0.0%) patient in group I responded to this
therapy (P = .016). Groups I and IIA had a significant difference for mean estimated blood loss (group I = 377.2 mL,
group II = 121.8 mL; P = .017) and requirement for transfusion (P = .013). More patients in group I required exten-
sive surgical treatment (P = .007), with six of these patients requiring vein patch angioplasty during their treatment.
More patients in group I also had infectious complications (n = 3) compared with group IIA (n = 1).
Conclusion: In comparison with complications that follow percutaneous arteriotomy when PSMC devices are not used
for hemostasis: (1) pseudoaneurysms after the use of PSMC devices are larger and do not respond to ultrasound com-
pression, (2) complications associated with PSMC devices result in more blood loss and increased need for transfusion
and are more likely to require extensive operative procedures, and (3) arterial infections after the use of PSMC devices
are more common and require aggressive surgical management. (J Vasc Surg 2001;33:688-93.)
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femoral artery complication after a percutaneous arteri-
otomy not associated with a PSMC device. The following
data were collected for each patient: age, type of catheteri-
zation, presenting complaints, method of diagnosis, type of
complication, surgical and nonsurgical management, and
other data seen in the Table: size of pseudoaneurysm,
response to ultrasound compression, infectious complica-
tions, estimated blood loss, need for transfusion, and type of
operation. Intraoperative photographs were reviewed, along
with perioperative radiographic studies. The actual number
of catheterizations performed during the time period was
not investigated. Only patients evaluated by the vascular
surgery service for a complication were included.
The statistical program SPSS 8.0 (SPSS, Inc, Chicago,
Ill) was used for data analysis. Significance was indicated by
P less than or equal to .05. Parametric data were analyzed
by independent samples t test. Nonparametric data were
analyzed with the Mann-Whitney test and χ2 analysis. 
RESULTS
A total of 25 patients were identified, with 11 patients in
group I and 14 patients in group II. Mean age for group I
was 60.4 years and group II was 67.1 years (P = .227).
Complications in group I occurred after both therapeutic (n
= 6) and diagnostic (n = 5) catheterizations. This was similar
to group II patients (P = .897), with eight therapeutic and six
diagnostic procedures performed. The average time from
procedure to vascular surgery consultation was 10.9 days
(range, 1-60) for group I and 11.0 days (range, 1-30) for
group II. This was not statistically different when analyzed by
Mann-Whitney U test (P = .211) and t test (P = .616).
Primary findings at presentation in group I included pul-
satile groin mass (n = 7), lower extremity ischemia (n = 3),
and hemorrhage (n = 1). Ultrasound scanning identified a
pseudoaneurysm in the patients (n = 7) diagnosed with a pul-
satile groin mass. Average pseudoaneurysm size was 5.8 cm
(range, 3-10) in greatest dimension. Ultrasound compres-
Proposed treatment algorithm after PSMC device–related complications.
sion was attempted in five of these patients, with a success
rate of 0.0% (n = 0). Angiography was performed in three
patients and showed occlusion of the common femoral artery
(CFA, n = 2) and a dissection with a high-grade stenosis (n =
1). In the patient admitted with hemorrhage, a 6 × 4-cm
pseudoaneurysm was discovered at surgery, but no preoper-
ative diagnostic study was performed. A summary of each
patient included in group I can be seen in the Table.
All patients in group II (n = 14) had a pulsatile groin
mass and a pseudoaneurysm confirmed by ultrasound scan-
ning (n = 13) or operative findings (n = 1). In one patient
the pseudoaneurysm was also seen on arteriography during
the catheterization. The size of the pseudoaneurysm was
not recorded in three patients. In the remaining patients 
(n = 11), the average pseudoaneurysm size was 2.8 cm
(range, 1.8-7.0) in greatest dimension. This was smaller
than the average size of pseudoaneurysms seen in group 
I (P = .003). Nine patients in group II underwent ultra-
sound compression. Successful thrombosis of the pseudo-
aneurysm was achieved in 66.6% (n = 6). Compared with
group I, the success of ultrasound compression in group II
was significantly better (P = .016). 
All patients in group I (n = 11) underwent surgery.
Description of each patient’s operative findings and surgical
therapy is seen in the Table. Each patient was given preop-
erative antibiotics. Of the eight patients admitted with a
pseudoaneurysm, five (62.5%) of the arteriotomies were
closed primarily. In two patients the PSMC device was found
in the subcutaneous tissue and fascia above the artery, and in
two others it had been partially deployed into the artery act-
ing to keep the arteriotomy open. Vein patch angioplasty
(VPA) was required to repair arterial lacerations in 37.5% 
(n = 3) of the patients with pseudoaneurysms. The lacera-
tions (n = 3) required debridement of the attenuated arter-
ial wall and averaged 5.3 mm in length. In all three of these
patients, the PSMC device broke or was removed in the
catheterization laboratory after being inserted into the
artery. In addition to VPA performed in these three patients,
VPA was also required to close the artery in two patients that
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were initially closed primarily and in one patient who was
diagnosed with arterial dissection. Ultimately, 54.5% (n = 6)
of the patients in group I required VPA during their treat-
ment. 
Three patients in group I were diagnosed with
ischemia and lower extremity neurologic signs: two with
thrombosis of the CFA and one with dissection and high-
grade stenosis of the CFA. Both patients with thrombosis
underwent thrombectomy and primary closure; the other
patient underwent a CFA endarterectomy and VPA. In
the patient with dissection, the PSMC device had captured
posterior wall plaque, apposing it to the anterior wall, cre-
ating a high-grade stenosis. In each patient in group I, the
PSMC device was removed when identified.
Three patients in group I (patients 1, 2, and 3 in the
Table) also had infectious complications. All three of these
patients had intraoperative cultures positive for methicillin-
resistant Staphylococcus aureus (MRSA). Patient 1 was
admitted with lower extremity ischemia resulting from
CFA thrombosis that was treated with embolectomy and
primary closure. Recurrent bleeding led to reoperation and
primary closure. Hemorrhage occurred three more times,
followed by VPA, vascular bypass grafting, and ligation of
the external iliac artery, respectively. Hip disarticulation
was required, and the patient ultimately died of multisys-
tem organ failure (MSOF). Patient 2 also underwent pri-
mary closure after being diagnosed with hemorrhage and 
a pseudoaneurysm. Three repeat bleeding episodes oc-
curred; surgical management included debridement and
primary closure, VPA, and finally ligation of the external
iliac artery and common iliac to superficial femoral artery
bypass via the obturator canal. Patient 3 did well after arte-
rial debridement and primary closure.
Eight (53.8%) patients in group II (group IIA) required
surgical intervention, and no patient needed reoperation dur-
ing the follow-up period. The six patients (group IIB) who
responded to ultrasound compression did not undergo
surgery. Seven patients in group IIA underwent pseudo-
aneurysm evacuation and closure of the arteriotomy. In all
Summary of the management for group I patients after the use of PSMC devices
No. Therapeutic Days US
of Age vs to Size US compression Diagnostic
patients (y) diagnostic Complications present PSA (cm) compression successful test
1 72 Therapeutic Lower extremity ischemia 10.0 No N/A N/A N/A A-gram
2 52 Therapeutic Hemorrhage 14.0 Yes 6.0 N/A N/A None
3 63 Therapeutic Pulsatile groin mass 13.0 Yes 3.0 No N/A US
4 48 Diagnostic Lower extremity ischemia 1.0 No N/A N/A N/A A-gram
5 56 Therapeutic Lower extremity ischemia 60.0 No N/A N/A N/A A-gram
6 53 Diagnostic Pulsatile groin mass 2.0 Yes 10.0 Yes No US
7 74 Therapeutic Pulsatile groin mass 2.0 Yes 4.0 Yes No US
8 56 Diagnostic Pulsatile groin mass 7.0 Yes 7.0 Yes No US
9 55 Diagnostic Pulsatile groin mass 1.0 Yes 3.5 Yes No US
10 56 Diagnostic Pulsatile groin mass 4.0 Yes 7.5 Yes No US
11 80 Therapeutic Pulsatile groin mass 6.0 Yes 6.0 No N/A US
*Also require VPA during treatment closure.
PSA, Pseudoaneurysm; US, ultrasound; A-gram, arteriogram; D, debridement; PC, primary closure; T, thrombectomy; PSMCD, percutaneous 
suture–mediated closing device.
seven patients the arteriotomy was amenable to primary clo-
sure. In one patient with an associated arteriovenous fistula,
the fistula was ligated, and the arteriotomy was closed pri-
marily. One patient in group IIA had development of a
superficial wound infection (MRSA) identified on postoper-
ative day 3 that resolved with local wound care and antibi-
otics. Because of the small patient population, there was no
statistical difference in the occurrence of infection between
groups I and II. No patient in group II died or had limb loss.
Analysis by t test showed a significant difference (P =
.017) in the estimated intraoperative blood loss between
group I (mean, 377.2 mL; range, 50-1150 mL) and
group IIA (mean, 121.8 mL; range, 75-225 mL). This
was also significant when the mean estimated blood loss
was transformed to normalize the two groups (P = .004).
Cross-tabulation and performance of a χ2 test also
revealed a significant difference (P = .005) in the require-
ment for transfusion between the two groups (n = 9 in
group I, n = 2 in group II). The transfusion requirement
for group I averaged 3.9 units per patient. 
DISCUSSION
The potential benefits of PSMC devices have led to their
widespread use after transfemoral diagnostic and therapeutic
catheterizations. Several early investigations report excellent
results with decreased complication rates compared with
manual compression for hemostasis.7,9 However, a recent
study showed that when compared with radial artery access,
PSMC device use for femoral arteriotomies was associated
with increased bleeding complications.12 Recent surgical liter-
ature has also questioned this low complication rate and has
suggested that a new pattern of complications is emerg-
ing.10,11 Whether this is related to an initial learning curve,
poor patient selection, or device malfunction has not been
ascertained. The goal of this study was not to determine the
complication rate of PSMC devices, nor do we attempt to
provide recommendations for their use. The purpose is to
describe our experience in the surgical management of vascu-
lar complications after the use of PSMC devices. We compare
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this with our surgical management and the type of femoral
complications that occur when PSMC devices are not used. It
should be noted that several PSMC devices are approved by
the Food and Drug Administration (FDA) and are available
for use. Perclose Techstar and Prostar were the only PSMC
devices used in the patients included in this study.
There was no statistical difference between groups I
and II with regard to age. In contrast to other published
series, the type of catheterization performed (therapeutic
vs diagnostic) did not predict the occurrence of complica-
tions and was performed with equivalent frequency (P =
.897) in each group.2,4,6 Also, the time period from
catheterization to presentation to our vascular surgery ser-
vice was similar in each group (P = .211). 
Several important differences, however, exist between
the complications that occurred with (group I) and without
(group II) the use of a PSMC device. First, the size of the
pseudoaneurysms in group I (mean, 6.2 cm) were signifi-
cantly larger (P = .003) than those in group II (mean, 2.9
cm). In 1994 Lumsden et al4 reported the average size of a
pseudoaneurysm after heart catheterization was 2.4 cm.
Franco et al3 also noted pseudoaneurysm size to be
between 1 and 3 cm in most of their patients. This is com-
parable to our control group. An exact explanation for the
difference in pseudoaneurysm size in our groups is not
available; however, it is likely that the larger arteriotomies
and arterial lacerations created during a PSMC device
mishap may be responsible for pseudoaneurysms of greater
dimensions. The direct operative approach to femoral
pseudoaneurysms has been well described and is our tech-
nique of choice for uncomplicated pseudoaneurysms; how-
ever, with larger or complicated pseudoaneurysms proximal
control at the external iliac artery may be preferred.3,5
The increased size of group I pseudoaneurysms led to
greater intraoperative blood loss (mean, 377.2 mL) than
the pseudoaneurysms treated with operation in group II
(mean, 121.8 mL). This was statistically significant with a
P value by t test of .017. The likelihood of requiring a
transfusion was also increased in group I compared with
Need Estimated
Operative for blood Transfusion
treatment reoperation loss (mL) needed Comments
D,PC,T* Yes (5) 200 Yes Failed bypass, hip disarticulation, died of MSOF
D,PC* Yes (3) 650 Yes Partial deployment of PSMCD, had obturator bypass, limb preserved
D,PC No 425 Yes Observed no reoperation
PC,T No 250 No PSMCD not found
VPA, endarterectomy* No 50 No Capture of posterior plaque by PSMCD
VPA,D No 300 Yes PSMCD removed in catheterization laboratory
VPA,D No 300 Yes PSMCD removed in catheterization laboratory
VPA,D No 275 Yes PSMCD removed in catheterization laboratory
PC No 300 Yes PSMCD partially deployed in artery
PC No 1150 Yes Fascial deployment of PSMCD
PC No 250 Yes Fascial deployment of PSMCD
after catheterization may occur with the use of PSMC
devices. For this reason, close attention to physical exami-
nation results is mandatory if the correct preoperative
study, if any, is to be obtained.
VPA has been described as an option for repairing large
arterial defects occasionally associated with pseudo-
aneurysms. Synthetic patches are used less often. Skillman
et al5 used VPA in treating six of 75 (8%) patients with
peripheral vascular complications after femoral arteriotomy
and traditional methods of hemostasis. Others also report
that arterial defects in this setting rarely need VPA for
repair.3,6 In contrast, four (36.3%) patients in group I
required VPA during the initial operation for appropriate
arterial closure. In three of these patients the PSMC device
was deployed and subsequently removed in the catheteri-
zation laboratory when satisfactory results were not
achieved. As pointed out by Eidt et al,11 the arteriotomy
can be enlarged by forceful removal of the PSMC device
after unsuccessful deployment. In addition to the four
patients mentioned above, VPA was performed in two
other patients during reoperation. Ultimately, six (53.5%)
patients in group I required VPA. The surgeon should be
aware that VPA is commonly required to repair the arterial
defects created by PSMC devices. 
Arterial infection after traditional compression therapy
after a percutaneous transluminal procedure is rare 
(< 1.0%). Periarterial hematoma, semisterile technique, and
foreign material within the arterial wall are all associated
with an increased infection rate.15,16 Superficial wound
infections most commonly respond to local therapy; how-
ever, a deep periarterial infection may result in significant
morbidity. Disruption of arterial suture lines is commonly
seen and may necessitate VPA, arterial ligation, interposi-
tion grafting, or vascular bypass grafting. Multiple reoper-
ations leading to amputation and death have been reported
in the setting of periarterial infections.17
Initially, the published infection rate with collagen plugs
inserted into femoral arteriotomies for hemostasis was
low.18,19 Recent surgical series have challenged this reported
low infection rate.11 Likewise, early reports found in the car-
diology literature did not show an increased infection rate
associated with PSMC devices when compared with com-
pression therapy.7,9 Eidt et al11 listed the FDA-published
infectious complications seen in the 200 most recent com-
plications that occurred with PSMC device use. Only three
infections were reported by the FDA.11 It is possible that
these initial complications reported by interventionalists may
not reflect the true incidence that is subsequently seen by
surgeons on patient readmission. As with collagen plugs, the
foreign material of a PSMC device placed under semisterile
conditions may also lead to increased infections.
The surgeon should have a low threshold for obtain-
ing intraoperative cultures when managing device-related
complications. Those patients with positive culture results
but no obvious sign of infection should be monitored
closely. Continuing empiric antibiotics with adjustments
made on the basis of Gram stain and culture results is rec-
ommended. An argument could be made for reexplo-
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group II (P = .005). Seven patients in group I received a
transfusion before surgical consultation. The transfusion
requirement for group I patients averaged 3.9 units per
patient during the hospitalization. This included the
amount of blood required to replace preoperative, intraop-
erative, and postoperative blood losses. Mean transfusion
requirement in the series by Lumsden et al4 was 1.9 units
per patient. We approached the pseudoaneurysms directly
in all group I patients except on two occasions. Perhaps
proximal control would have been a better choice for these
large pseudoaneurysms. This technique should be strongly
considered when managing PSMC device complications. 
Another interesting difference between the pseudo-
aneurysms in the two groups is noted. Five patients in group
I underwent ultrasound compression of a pseudoaneurysm
without successful resolution. All of these patients required
operative intervention. Ultrasound compression, however,
was more effective (P = .016) in group II patients, with two
thirds of the pseudoaneurysms resolving. This is comparable
to other studies that report success of ultrasound compres-
sion to be 70% to 90%.6,13 The failure of ultrasound com-
pression in group I may again be explained by the larger
arteriotomy that is common after PSMC device use.
Furthermore, in two group I patients, the PSMC device had
been partially deployed into the arterial wall and was acting
to keep the artery open. Ultrasound compression is often 
a painful and time-consuming procedure.14 We no longer
recommend it in the treatment of pseudoaneurysms after
the use of PSMC devices (Figure).
Thrombin injection under ultrasound guidance is
gaining popularity as a first-line treatment for pseudo-
aneurysms. However, there has been no report of use of
thrombin injection for pseudoaneurysms associated with a
PSMC device. Thrombin injection would likely be suc-
cessful in this setting; however, we maintain that removing
the suture placed by the PSMC device is mandatory. The
suture may harbor bacteria and serve as a nidus for infec-
tion. In summary, thrombin injection for PSMC
device–related complications should be used with caution
until further data regarding this subject are available.
Historically, pseudoaneurysm is the most common
complication after a percutaneous transluminal arterial
procedure.1,3 We found this to be true in both of our
groups. As a result, ultrasound scanning is usually the 
only diagnostic test needed. In group II all patients were
diagnosed with a pseudoaneurysm, and ultrasound scan-
ning confirmed this in 12 (85.6%) of the patients.
Angiography is rarely needed in this group of patients to
diagnose the pseudoaneurysm.2 The pseudoaneurysm
diagnosed by angiography in group II was seen at the 
termination of the catheterization procedure. Pseudo-
aneurysm was also the most common complication in
group I; however, in four (36%) patients the primary find-
ing at presentation was not a pseudoaneurysm. One of
these patients was taken directly to surgery for hemor-
rhage. Three (27%) other patients were diagnosed with
lower extremity ischemia and subsequently underwent
angiography. A unique set of injuries not traditionally seen
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ration and vascular bypass in this setting, but more expe-
rience is needed before making this recommendation.
Four patients in our series had development of infec-
tious complications: three patients in group I (Table) and
one patient in group II. The patient in group II had a
superficial wound infection that responded to local ther-
apy and antibiotics. One of the patients in group I (patient
3) did well after aggressive debridement, primary arterial
closure, and a course of intravenous antibiotics. Two
patients (patients 1 and 2) required a total of eight reop-
erations after experiencing bleeding episodes from arterial
suture line associated with MRSA wound cultures. Vein
patch angioplasty was used in their treatment, and both
eventually required arterial ligation. Patient 1 required hip
disarticulation and ultimately died of MSOF. Patient 2
underwent common iliac–to–superficial femoral artery
bypass grafting via the obturator canal along with external
iliac artery ligation and is sepsis free at 6 months. 
Perhaps earlier conversion to arterial ligation and
extra-anatomic reconstruction would have improved the
care of these two patients. This has been proposed for the
management of infected groins at femoral anasto-
moses.20,21 Alternatively, performing a temporary in situ
repair with VPA may provide adequate time for patient
stabilization (Figure).22 This would allow for a more con-
trolled environment when the definitive repair is under-
taken. Strong consideration should be given to this option
when a patient is diagnosed with hemorrhage after pri-
mary closure of the artery injured by a PSMC device.
Successful in situ repair can be performed in the face of
infection, but these patients must be monitored closely.
CONCLUSION
In selected patients PSMC devices have been shown to
be effective in achieving hemostasis with low complication
rates after percutaneous interventional procedures. Recent
investigations have questioned this low complication rate
and have shown that when complications result, they may
be quite extensive. Our experience has shown that
pseudoaneurysms after the use of PSMC devices are larger
and do not respond to ultrasound compression. Second,
complications associated with PSMC devices result in
more blood loss and transfusion requirements and are
more likely to require extensive operative interventions.
Finally, arterial infections after use of PSMC devices are
more common and require aggressive surgical manage-
ment if catastrophic complications are to be avoided.
We thank Pat Lewis RN, Maggie Hamblen, Robin
Harvey, and Michael D. Biderman, PhD, for their assis-
tance in preparing this manuscript. 
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